Last reviewed · How we verify
Aramchol free acid
Aramchol inhibits stearoyl-CoA desaturase 1 (SCD1), an enzyme that converts saturated fatty acids to monounsaturated fatty acids, thereby reducing hepatic lipogenesis and improving liver metabolism.
Aramchol inhibits stearoyl-CoA desaturase 1 (SCD1), an enzyme that converts saturated fatty acids to monounsaturated fatty acids, thereby reducing hepatic lipogenesis and improving liver metabolism. Used for Non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease (NAFLD).
At a glance
| Generic name | Aramchol free acid |
|---|---|
| Also known as | 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid, Two tablets of Aramchol free acid |
| Sponsor | Galmed Pharmaceuticals Ltd |
| Drug class | SCD1 inhibitor |
| Target | Stearoyl-CoA desaturase 1 (SCD1) |
| Modality | Small molecule |
| Therapeutic area | Hepatology |
| Phase | Phase 3 |
Mechanism of action
By blocking SCD1, aramchol decreases the production of monounsaturated fatty acids in the liver, which reduces hepatic steatosis and improves insulin sensitivity. This mechanism addresses the underlying metabolic dysfunction in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), reducing liver fat accumulation and inflammation.
Approved indications
- Non-alcoholic steatohepatitis (NASH)
- Non-alcoholic fatty liver disease (NAFLD)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Elevated liver enzymes
Key clinical trials
- A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) (PHASE3)
- Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (PHASE1)
- Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment (PHASE1)
- An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aramchol free acid CI brief — competitive landscape report
- Aramchol free acid updates RSS · CI watch RSS
- Galmed Pharmaceuticals Ltd portfolio CI